{"id":36485,"date":"2018-03-28T15:43:00","date_gmt":"2018-03-28T13:43:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/"},"modified":"2024-07-29T08:11:45","modified_gmt":"2024-07-29T06:11:45","slug":"ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/","title":{"rendered":"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9."},"content":{"rendered":"<p> <\/p>\n<p><b>Paris, France, 28 mars 2018<\/b>\u00a0\u2014 Ipsen (Euronext : IPN ; ADR : IPSEY) a annonc\u00e9 aujourd\u2019hui que l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA), l\u2019autorit\u00e9 de sant\u00e9 europ\u00e9enne, a valid\u00e9 le d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.<br \/>Cette demande s\u2019appuie sur les r\u00e9sultats de l\u2019\u00e9tude internationale de phase 3 CELESTIAL qui a atteint son crit\u00e8re d\u2019\u00e9valuation principal de survie globale (OS), le cabozantinib ayant permis d\u2019obtenir une am\u00e9lioration statistiquement significative et cliniquement pertinente de la survie globale m\u00e9diane en comparaison au placebo chez des patients atteints d\u2019un carcinome h\u00e9patocellulaire (CHC) avanc\u00e9, pr\u00e9c\u00e9demment trait\u00e9s par soraf\u00e9nib.<\/p>\n<p>Le Docteur Alexandre Lebeaut, Vice-Pr\u00e9sident Ex\u00e9cutif, R&amp;D et Chief Scientific Officer, Ipsen, a d\u00e9clar\u00e9 :<\/p>\n<blockquote>\n<p>\u00ab Cette \u00e9tape constitue une avanc\u00e9e importante dans le programme de d\u00e9veloppement du cabozantinib ciblant les tumeurs solides, avec la possibilit\u00e9, si la nouvelle indication est approuv\u00e9e, de fournir aux patients atteints de CHC avanc\u00e9 \u2013 qui repr\u00e9sente encore un besoin m\u00e9dical insatisfait \u2013 un nouveau traitement syst\u00e9mique oral. \u00bb<\/p>\n<\/blockquote>\n<p><\/p>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556,3560],"tags":[],"class_list":["post-36485","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","category-oncology-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-29T06:11:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\"},\"headline\":\"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.\",\"datePublished\":\"2018-03-28T13:43:00+00:00\",\"dateModified\":\"2024-07-29T06:11:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/\"},\"wordCount\":230,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\",\"Oncologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/\",\"name\":\"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2018-03-28T13:43:00+00:00\",\"dateModified\":\"2024-07-29T06:11:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.","og_url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/","og_site_name":"Global","article_modified_time":"2024-07-29T06:11:45+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352"},"headline":"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.","datePublished":"2018-03-28T13:43:00+00:00","dateModified":"2024-07-29T06:11:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/"},"wordCount":230,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate","Oncologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/","url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/","name":"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9.","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2018-03-28T13:43:00+00:00","dateModified":"2024-07-29T06:11:45+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/YmJlMWQ5MzAtZGExNS00NDk2LTg1NTItOTAzOWQ4NjBjY2UwLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-validation-par-lema-du-depot-de-la-demande-de-nouvelle-indication-de-cabometyx-cabozantinib-pour-des-patients-prealablement-traites-pour-carcinome-hepatocellulaire-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen annonce la validation par l\u2019EMA du d\u00e9p\u00f4t de la demande de nouvelle indication de Cabometyx\u00ae (cabozantinib) pour des patients pr\u00e9alablement trait\u00e9s pour Carcinome H\u00e9patocellulaire (CHC) avanc\u00e9."}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36485\/revisions"}],"predecessor-version":[{"id":62849,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36485\/revisions\/62849"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}